Publications by authors named "Suzanne Trudel"

82Publications

Syngeneic transplants for multiple myeloma - a single center experience and review of the literature.

Leuk Lymphoma 2020 Sep 14:1-4. Epub 2020 Sep 14.

Princess Margaret Cancer Centre, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1817443DOI Listing
September 2020

Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.

Future Oncol 2020 Sep 2. Epub 2020 Sep 2.

Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto M5G2C1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0521DOI Listing
September 2020

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy.

JAMA Oncol 2020 Feb;6(2):293-294

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.5098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902180PMC
February 2020

Incorporating isatuximab in the treatment of multiple myeloma.

Authors:
Suzanne Trudel

Lancet 2019 12 14;394(10214):2045-2047. Epub 2019 Nov 14.

Princess Margaret Cancer Centre, Toronto, ON M5G 1Z5, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)32684-4DOI Listing
December 2019

Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.

Clin Lymphoma Myeloma Leuk 2019 04 20;19(4):e195-e203. Epub 2018 Dec 20.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.007DOI Listing
April 2019

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.

Clin Lymphoma Myeloma Leuk 2018 03 5;18(3):225-234. Epub 2018 Jan 5.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.12.009DOI Listing
March 2018

Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2016 07 10;16(7):387-94. Epub 2016 May 10.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.04.012DOI Listing
July 2016

Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity.

Mol Cell Proteomics 2015 Mar 13;14(3):695-706. Epub 2015 Jan 13.

From the ‡Molecular Structure and Function, The Hospital For Sick Children, 686 Bay Street, Toronto, M5G 0A4, Canada; ‡‡Departments of Molecular Genetics, Medical Science Building, Room 4386, 1 King's College Circle, Toronto, ON M5S 1A8, Canada; **The Princess Margaret Cancer Center, 610 University Avenue, M5G 2M9, Toronto, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/mcp.M114.044404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349988PMC
March 2015

Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant.

Leuk Lymphoma 2015 24;56(9):2668-73. Epub 2015 Feb 24.

a Department of Medical Oncology and Hematology , Princess Margaret Cancer Centre , Toronto , ON , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.1003057DOI Listing
August 2016

Differential regulation of FGFR3 by PTPN1 and PTPN2.

Proteomics 2015 Jan 17;15(2-3):419-33. Epub 2014 Dec 17.

Program in Molecular Structure and Function, Hospital for Sick Children, Toronto, Canada; Department of Molecular Genetics, University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pmic.201400259DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032629PMC
January 2015

Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.

Br J Haematol 2015 Jan 22;168(1):46-54. Epub 2014 Aug 22.

Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13100DOI Listing
January 2015

Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.

Cancer Res 2014 Sep 3;74(17):4772-82. Epub 2014 Jul 3.

Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0130DOI Listing
September 2014

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.

Leuk Lymphoma 2015 Jan 27;56(1):232-5. Epub 2014 Jun 27.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Center , Toronto, ON , Canada.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2014.89
Publisher Site
http://dx.doi.org/10.3109/10428194.2014.893304DOI Listing
January 2015

Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site.

J Oncol Pharm Pract 2015 Aug 29;21(4):285-92. Epub 2014 Apr 29.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1078155214533367
Publisher Site
http://dx.doi.org/10.1177/1078155214533367DOI Listing
August 2015

Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.

Leuk Lymphoma 2014 Oct 24;55(10):2284-9. Epub 2014 Feb 24.

Princess Margaret Cancer Center, Department of Medical Oncology and Hematology , Toronto, ON , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.873537DOI Listing
October 2014

Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.

Br J Haematol 2014 Mar 25;164(5):722-8. Epub 2013 Nov 25.

Department of Medical Oncology and Haematology, Princess Margaret Cancer Center, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12673DOI Listing
March 2014

A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells.

Bioorg Med Chem 2013 Sep 9;21(17):5618-28. Epub 2013 May 9.

Department of Chemistry, University of Toronto, 3359 Mississauga Road North, Mississauga, ON, L5L 1C6, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2013.04.080DOI Listing
September 2013

D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.

Br J Haematol 2013 Jun 18;161(6):802-10. Epub 2013 Apr 18.

Hematology, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12325DOI Listing
June 2013

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.

Cancer Chemother Pharmacol 2013 Apr 25;71(4):867-81. Epub 2013 Jan 25.

Department of Hematology/Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2078-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832139PMC
April 2013

Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.

Clin Lymphoma Myeloma Leuk 2013 Feb 27;13(1):25-31. Epub 2012 Oct 27.

Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2012.08.008DOI Listing
February 2013

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.

Leuk Lymphoma 2013 Mar 2;54(3):555-60. Epub 2013 Jan 2.

Princess Margaret Hospital, Department of Medical Oncology and Hematology, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.719614DOI Listing
March 2013

Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy.

Am J Hematol 2012 Aug 28;87(8):822-3. Epub 2012 May 28.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23235DOI Listing
August 2012

Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.

Int J Hematol 2012 Jul 10;96(1):125-31. Epub 2012 May 10.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, 620 University Avenue, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-012-1090-1DOI Listing
July 2012

Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.

Biol Blood Marrow Transplant 2012 May 4;18(5):773-9. Epub 2011 Nov 4.

Princess Margaret Hospital, Division of Medical Oncology and Hematology, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2011.10.044DOI Listing
May 2012

Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.

Bioorg Med Chem Lett 2011 Sep 30;21(18):5605-9. Epub 2011 Jun 30.

Department of Chemistry, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON, Canada L5L 1C6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2011.06.056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530782PMC
September 2011

Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.

Clin Cancer Res 2011 Jul 1;17(14):4693-704. Epub 2011 Jun 1.

Department of Medical Oncology-Hematology, Princess Margaret Hospital, McLaughlin Centre for Molecular Medicine, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-3097DOI Listing
July 2011

The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence.

Mol Pharmacol 2011 Apr 10;79(4):672-80. Epub 2011 Jan 10.

Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, the First Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.110.068122DOI Listing
April 2011

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma.

Blood 2010 Jun 1;115(23):4787-97. Epub 2010 Apr 1.

Ontario Cancer Institute/Princess Margaret Hospital, Campbell Family Institute for Cancer Research, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-07-230508DOI Listing
June 2010

Measurement of protein phosphorylation stoichiometry by selected reaction monitoring mass spectrometry.

J Proteome Res 2010 May;9(5):2752-61

McLaughlin Centre for Molecular Medicine, MaRS East Tower, 101 College Street, Toronto, M5G 1L7, Canada.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/abs/10.1021/pr100024a
Publisher Site
http://dx.doi.org/10.1021/pr100024aDOI Listing
May 2010

Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.

Proc Natl Acad Sci U S A 2009 Nov 9;106(47):20127-32. Epub 2009 Nov 9.

Molecular Structure and Function Program, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0910957106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2775037PMC
November 2009

Spontaneous remission in a patient with t(4;14) translocation multiple myeloma.

J Clin Oncol 2009 Nov 5;27(33):e194-7. Epub 2009 Oct 5.

Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.22.0392DOI Listing
November 2009

Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.

Biol Blood Marrow Transplant 2009 Jun 9;15(6):686-93. Epub 2009 Apr 9.

Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale,AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2009.02.013DOI Listing
June 2009

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

J Clin Oncol 2008 Oct 21;26(29):4777-83. Epub 2008 Jul 21.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Suite 5-207, Toronto, Ontario, M5G 2M9 Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.14.2372DOI Listing
October 2008

Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor.

J Proteome Res 2008 Mar 14;7(3):1067-77. Epub 2008 Feb 14.

Program in Molecular Structure and Function, Hospital for Sick Children, Department of Molecular Genetics, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/abs/10.1021/pr7006363
Publisher Site
http://dx.doi.org/10.1021/pr7006363DOI Listing
March 2008

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.

Blood 2007 Jun 1;109(12):5430-8. Epub 2007 Mar 1.

Hematology-Oncology, Princess Margaret Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2006-10-047951DOI Listing
June 2007

The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.

Clin Cancer Res 2007 Jan;13(2 Pt 1):621-9

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, 620 University Avenue, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-06-1526DOI Listing
January 2007

MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.

Blood 2006 Nov 18;108(10):3465-71. Epub 2006 Jul 18.

Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2006-04-017087DOI Listing
November 2006

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.

Blood 2006 May 7;107(10):4039-46. Epub 2006 Feb 7.

University Health Network, Princess Margaret Hospital, McLaughlin Centre of Molecular Medicine, 620 University Avenue, Rm 8204, Toronto, Ontario, Canada M5G 2C1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-10-4179DOI Listing
May 2006

Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.

J Clin Oncol 2005 Oct 29;23(28):7069-73. Epub 2005 Aug 29.

Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2005.17.129
Publisher Site
http://dx.doi.org/10.1200/JCO.2005.17.129DOI Listing
October 2005

Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma.

Blood 2005 Jul 10;106(1):353-5. Epub 2005 Mar 10.

Department of Laboratory Hematology, Princess Margaret Hospital/University Health Network, McLaughlin Center for Molecular Medicine, University of Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-01-0033DOI Listing
July 2005

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

Blood 2005 Apr 14;105(7):2941-8. Epub 2004 Dec 14.

Department of Medical Oncology, University Health Network, Princess Margaret Hospital and McLaughlin Centre of Molecular Medicine, University of Toronto, 620 University Ave, Rm 8-204, Toronto, ON, Canada M5G 2C1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2004-10-3913DOI Listing
April 2005

Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.

Cancer Res 2004 May;64(9):3271-5

Division of Experimental Therapeutics, Toronto General Research Institute, McLaughlin Centre for Molecular Medicine, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.can-03-3764DOI Listing
May 2004

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.

Br J Haematol 2004 Mar;124(5):595-603

Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2004.04814.xDOI Listing
March 2004

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

Blood 2004 May 8;103(9):3521-8. Epub 2004 Jan 8.

Department of Medicine, Weill Medical College and Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2003-10-36
Publisher Site
http://dx.doi.org/10.1182/blood-2003-10-3650DOI Listing
May 2004

Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance.

Blood 2002 Nov 25;100(10):3819-21. Epub 2002 Jul 25.

Division of Experimental Therapeutics, Toronto General Research Institute, and the Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-02-0608DOI Listing
November 2002